TVTX · Travere Therapeutics

The thesis

Travere Therapeutics' kidney drug FILSPARI cleared the revenue benchmark in the third quarter, but the shares have not responded and patient demand softened slightly. The fourth-quarter report and the 1 December 2026 CEO handover now decide whether the launch keeps compounding.

Travere reported on 2 November 2026 that FILSPARI US net sales were $200.2 million, up 120% from a year earlier and well above the second quarter's $141.1 million. Total revenue was $224.6 million against $164.9 million in the third quarter of 2025. New patient start forms were 1,932, below the 2,012 received in the second quarter.

The shares closed at $51.63 on 9 November 2026, 23.5% below the 52-week high of $67.52. The three-month price change was a decline of 16.9%, and the 14-day relative strength index (RSI), a momentum gauge on which readings under 30 mark heavy selling, was 47.8. The close on 27 October was $50.88, so the shares are about where they were before the report.

The story is well known: the launch is well known, the revenue beat on 2 November produced no visible re-rating, and analysts are trimming targets. The sales condition was met. The start-form condition was not.

Bullish and bearish views on Travere Therapeutics, Inc.

The bull case on Travere Therapeutics, Inc. (TVTX), in brief: sales cleared the benchmark by a wide margin. The bear case: start forms fell in the first full FSGS quarter.

Bull case

• Sales cleared the benchmark by a wide margin. FILSPARI US net sales were $200.2 million in Q3 2026, against $141.1 million in Q2 2026 and $90.9 million in Q3 2025. Benzinga reported total sales of $224.563 million against a $195.292 million estimate.
• The FSGS launch has no approved competitor. Management cited "encouraging early launch momentum" in focal segmental glomerulosclerosis (FSGS) in the 2 November release. A Phase 4 study, SPARLIGHT, is expected to enrol its first patient by year-end 2026.
• Clinical data keep supporting the drug. Travere's release cited a 48% mean proteinuria reduction at week 108 in a DUPLEX post hoc analysis, against 27% with irbesartan. It also cited 75% complete proteinuria remission among 12 patients in the SPARTAN final analysis in IgA nephropathy (IgAN).
• Cash funds the pipeline. Cash, cash equivalents and marketable securities were $471.8 million at 30 September 2026. Pegtibatinase's Phase 3 HARMONY study, with about 70 patients planned, is due to report topline results in the second half of 2027.
• Analyst targets sit far above the price. Guggenheim kept Buy and set a $78 target on 4 November, Canaccord kept Buy and raised its target to $72 the same day, and Leerink kept Outperform with a $67 target on 5 November. The close on 9 November was $51.63.
• FSGS patent coverage runs long. On 23 September 2026, Travere said the US Patent and Trademark Office had allowed a method-of-use patent in FSGS, with coverage expected into October 2037.

Bear case

• Start forms fell in the first full FSGS quarter. Travere received 1,932 new patient start forms in Q3 2026, against 2,012 in Q2. Start forms feed later sales, so a second decline would weaken the Q1 2027 outlook.
• Q4 sales carry an inventory drag. Travere said about $8 million of Q3 FILSPARI sales reflected specialty-pharmacy inventory growth and expects Q4 sales to be reduced by roughly the same amount. It also expects full-year gross-to-net discounts in the mid-20% range.
• Losses widened on a licensing charge. The Q3 GAAP net loss was $52.3 million, or $0.55 per share, including a $113.1 million in-process R&D expense for the Everest Medicines civorebrutinib licence. The non-GAAP net loss was $29.6 million, or $0.31 per share, against a $(0.06) estimate.
• Analysts are lowering targets. Guggenheim cut its target to $78 from $89 on 4 November, and Leerink lowered its target to $67 on 5 November.
• A CEO handover lands mid-launch. Eric Dube steps down for health and family reasons; Bradley L. Campbell takes over on 1 December 2026. The 21 September announcement carried no business update.
• The older products are shrinking. Tiopronin product sales were $20.0 million in Q3 2026, down from $22.3 million in Q3 2025.
• IgAN competition is growing. Novartis's Fabhalta and Vera Therapeutics' atacicept compete for IgAN patients. Dube's Form 4, filed 18 September 2026, also records option exercises and sales on 15–17 September under a Rule 10b5-1 trading plan adopted 16 June 2026.

Price setup

The shares closed at $51.63 on 9 November 2026, per adjusted daily closes. That is 23.5% below the 52-week high of $67.52 and about 3% above the $50 round-number level, which sits just under the $50.88 close of 27 October.

Recent closes show a downtrend that has flattened: $62.76 on 18 September, $56.85 on 1 October, $53.27 on 14 October, $50.88 on 27 October and $51.63 on 9 November. The RSI has recovered from 27.5 on 14 October to 47.8, so selling pressure has eased.

Crowding evidence is limited. The earnings date has passed, and no heavy retail attention or share issuance is visible in company news. The $525 million of convertible notes due 2032 carry a conversion price near $64.90, close to the 52-week high.

Catalysts ahead

• 1 December 2026: Bradley L. Campbell becomes president and CEO. A new chief executive takes over mid-launch; any change to commercial priorities, spending or guidance would show here.
• 31 December 2026: Year-end targets: civorebrutinib US IND submission and first patient in the SPARLIGHT Phase 4 FSGS study. Shows whether the pipeline additions funded by the Everest deal stay on the schedule Travere gave on 2 November 2026.
• ~February 2027 (est.): Q4 and full-year 2026 results. First quarter that absorbs the roughly $8 million inventory drag; settles whether FILSPARI sales hold above $200.2 million.

What would change the view

A daily close below $50, a round-number level under the $51.63 close of 9 November 2026 and just under the October low. A fourth-quarter FILSPARI US net sales result below the third quarter's $200.2 million, or a further drop in patient start forms, would also break the commercial case.

The risks this note tracks, each with what would confirm it:

• Patient demand is flattening: new start forms fell in the first full FSGS quarter. Confirmed by: Q4 2026 patient start forms below the 1,932 received in Q3, or FILSPARI US net sales below $200.2 million.
• Inventory normalisation and a mid-20% gross-to-net discount depress reported Q4 sales. Confirmed by: Q4 FILSPARI US net sales growth that stalls once the roughly $8 million Q3 inventory build reverses.
• The CEO handover on 1 December prompts a strategy reset or commercial departures. Confirmed by: changes to launch priorities, spending or senior commercial staff announced around or after 1 December 2026.
• IgAN competitors take share from FILSPARI. Confirmed by: falling start forms alongside reported launch gains for Novartis's Fabhalta or Vera's atacicept.
• Losses and pipeline spending keep widening after the civorebrutinib deal. Confirmed by: Non-GAAP net loss above Q3's $29.6 million, or cash falling well below $471.8 million without a matching sales gain.

What it trades with

Ligand Pharmaceuticals (LGND) holds a sparsentan royalty, so its royalty line gives an outside read on FILSPARI demand. Novartis (Fabhalta) and Vera Therapeutics (atacicept) are the IgAN competitors whose launch data bear on Travere's start forms. Everest Medicines is the licensing partner on civorebrutinib. The shares trade with small and mid-cap biotech sentiment more than with a single theme.